MAFTRR: A Potential Drug Target for Neurodegenerative Diseases

Target Name: MAFTRR

NCBI ID: G102467146

MAFTRR

Other Name(s): Linc-MAF-4 | LincMAF4 | lincMAF4 | linc-MAF-4 | MAF transcriptional regulator RNA

MAFTRR: A Potential Drug Target for Neurodegenerative Diseases

MAFTRR (Maltase-?±-Fucosinin) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cellular processes in the body and has been identified as a potential drug target in the field of neurodegenerative diseases.

The protein MAFTRR is composed of four subunits: alpha, beta, gamma, and delta. These subunits give the protein its unique structure and function. alpha subunit is the catalytic subunit that contains the active site for the enzyme's catalytic activity. beta subunit is the structural subunit that provides the protein with its unique 3D structure. gamma subunit is a non-catalytic subunit that plays a role in the regulation of the alpha subunit's activity. And delta subunit is a non-catalytic subunit that plays a role in the regulation of the gamma subunit's activity.

MAFTRR is a transmembrane protein, which means that it spans the cell membrane and is located outside the cytoplasm. It is involved in a wide range of cellular processes, including metabolism, inflammation, and signaling. One of the most well-known functions of MAFTRR is its role in the regulation of cellular energy metabolism. MAFTRR is involved in the citric acid cycle, also known as the Krebs cycle or TCA cycle, which is a process that generates energy in the form of ATP from glucose.

In neurodegenerative diseases, MAFTRR has been implicated in the development and progression of a wide range of disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and the buildup of neurofibrillary tangles and other abnormally formed proteins in the brain.

One of the potential reasons for the involvement of MAFTRR in neurodegenerative diseases is its role in the regulation of cellular signaling pathways. MAFTRR has been shown to play a role in the regulation of several signaling pathways that are involved in the development and progression of neurodegenerative diseases. For example, MAFTRR has been shown to play a role in the regulation of the JNK signaling pathway, which is involved in the regulation of cellular stress responses and the development of neurodegenerative diseases.

Another potential reason for the involvement of MAFTRR in neurodegenerative diseases is its role in the regulation of cellular metabolism. MAFTRR is involved in the regulation of cellular metabolism by controlling the levels of different cellular fuels, including glucose and ketones. The levels of these fuels are critical for the proper functioning of the cell and the maintenance of cellular health. If the levels of these fuels are imbalanced, it can lead to the development of neurodegenerative diseases.

In conclusion, MAFTRR is a protein that is involved in a wide range of cellular processes and has been implicated in the development and progression of neurodegenerative diseases. Its role in the regulation of cellular energy metabolism and signaling pathways makes it an attractive drug target for the development of new treatments for these disorders. Further research is needed to fully understand the role of MAFTRR in neurodegenerative diseases and to develop effective treatments.

Protein Name: MAF Transcriptional Regulator RNA

The "MAFTRR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAFTRR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets